Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00183248 · ClinicalTrials.gov registry record · Phase 1
Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
A Phase 1 study, sponsored by University of Miami.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00183248 is a Phase 1 study that has completed, run by University of Miami. The registered enrollment target is 9 participants.
The verdict
NCT00183248, a Phase 1 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
Alemtuzumab is a man-made antibody used to treat certain blood disorders. This study will evaluate treatment of kidney transplant recipients with alemtuzumab and other immune system suppressing medications with or without infusions of bone marrow stem cells from the kidney donor. The purpose of this study is to find out which strategy is more effective in preventing organ rejection and maintaining patient health.
Interventions
- DRUG Sirolimus
- DRUG Alemtuzumab
- DRUG Tacrolimus
- DRUG Mycophenolate mofetil
- PROCEDURE Donor bone marrow stem cell infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2004-09 |
| Est. Completion | 2009-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00183248
The ClinicalTrials.gov registry entry for NCT00183248 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Sirolimus is the first listed.
NCT00183248 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00183248 about?
NCT00183248 is a clinical study titled "Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients". Alemtuzumab is a man-made antibody used to treat certain blood disorders. This study will evaluate treatment of kidney transplant recipients with alemtuzumab and other immune system suppressing medications with or without infusions of bone marrow stem cells from the kidney donor. The purpose of this...
What is the current status of trial NCT00183248?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2004-09. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00183248?
The interventions under investigation include: Sirolimus (DRUG), Alemtuzumab (DRUG), Tacrolimus (DRUG), Mycophenolate mofetil (DRUG), Donor bone marrow stem cell infusion (PROCEDURE).
Who is sponsoring clinical trial NCT00183248?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.